Cambrian

Muscle is a key metabolic organ, and as GLP-1-based therapies reshape obesity treatment, a new clinical question is emerging: how do we ensure weight loss doesn't come at the expense of muscle? In our latest blog, our team explores why muscle preservation matters for long-term metabolic health, physical function, and healthy aging, and which patient populations may be most vulnerable. Read more: cambrianbio.com/blogs/muscle-m… #metabolism #metabolichealth #glp1

A thoughtful provocation in Nature Aging by our CEO @JamesPeyer: are GLP-1 receptor agonists gerotherapeutics, or are they just treatments for obesity? It's a question worth sitting with. The answer shapes how we design drugs, define patient populations, and ultimately measure success in a field that's still working out what it means to treat aging itself. Read the full publication here: nature.com/articles/s4358…

We're thrilled to announce positive Phase 1b clinical data for ATX-304, the first AMPK Network Activator to enter clinical development, presented at the American Diabetes Association's 86th Scientific Sessions. For the first time, we have demonstrated activity of an AMPK Network Activator in humans, with statistically significant improvements in liver fat, visceral adipose tissue, triglycerides, adiponectin, and resting metabolic rate in adults with obesity and prediabetes. The overall tolerability profile was comparable to placebo, with no adverse events indicative of mitochondrial failure, including no increase in continuously monitored core body temperature or 24-hour heart rate. A companion mechanistic poster confirmed that ATX-304 activates AMPK without decreasing cellular ATP levels, distinguishing it from prior AMPK-targeting approaches. We look forward to advancing ATX-304 into Phase 2 studies REWIRE-1 and REWIRE-2, evaluating exercise mimetic effects and muscle-sparing weight loss. Read the full release: cambrianbio.com/news-and-publi…

Happening today ‼️ @TheEndoSociety

This Sunday, 7/13‼️Our CEO @JamesPeyer is headed to @TheEndoSociety to present new data on the efficacy of ATX-304, our lead drug. Check out the press release to learn more 👇 cambrianbio.com/news-and-publi…

One of the most hollow critiques of translating discoveries about aging biology – “they will only be for the rich.” Demand curve says no. Preventative medicines are cheaper than other drugs and these will be among the best preventatives of all time. linkedin.com/pulse/medicine…

This newsletter is meant to be my own thinking and I try to be a bit more provocative here, so the views I express might not always reflect the position of @CambrianBio, which is much larger than me alone. linkedin.com/pulse/preventa…

You can learn more about the historical disparities of women’s health on the @OvivaTx website. While you're there, be sure to explore the incredible work they're doing to improve women’s health through groundbreaking biomedical research! ovivatx.com/about

But today, as we celebrate women and the progress made, let's remember that our work isn't done. We must continue pushing for a future where women's health is prioritized, ensuring that every woman receives the care she deserves.

Happy International Women’s day! Here are some fun facts about women’s health 👇

While we don't endorse chasing people down for snacks, our goal is to enable everyone to live as Dyna-Mitally through later years! 😉 #DinamitaDinero

Awesome news from our friends at @bioagelabs, congratulations!

To learn more about ATX-304 check out this blog by James: cambrianbio.com/blogs/atx-304-…

Check out the full interview for free here: m.youtube.com/watch?v=77zmaM…

Do you consider the potential impact of medical interventions on individuals' motivation to make difficult lifestyle changes, particularly in cases such as #obesity, where lifestyle changes are challenging but essential for improving health outcomes? 👇